Publié il y a 5 ans
May 2018
SYNSIGHT has received the certified Genopole as an innovative company in drug discovery and can integrate the incubator.
39
2
SYNSIGHT
Société
|
France
Onglets principaux
A propos de votre organisation
SYNSIGHT’s platform encompasses Artificial Intelligence, Molecular Modeling and High-Content Screening to rationalize and accelerate drug discovery projects of its partners.
La capacité prédictive de l’intelligence artificielle alliée à la capacité descriptive et explicative de la modélisation moléculaire, enrichie de données expérimentales quantitatives et fonctionnelles (permettant d’éduquer le modèle) constitue la plateforme de SYNSIGHT et sa valeur différenciante.
Actualités
/5
Publié il y a 5 ans
June 2018
SYNSIGHT obtains the certificate of HEC Challenge+ dedicated to entrepreneurs of innovative companies. Cyril Bauvais and Guillaume Bollot present their elevator pitch after 9 months of formation at HEC Campus.
Publié il y a 5 ans
September 2018
SYNSIGHT is honored to participate in AI for Health, in Paris on September 2018. During this exciting event, SYNSIGHT presented is activity and Cyril Bauvais (CEO) exchanged about its vision related to AI in drug discovery. Thank you, Damien Gromier for inviting us to this exciting event, and Pierre-Antoine Beaudouin, for the great debate!
Publié il y a 5 ans
September 2018
SYNSIGHT is proud to announce the launch of a state-of-the-art structural/biophysics unit within the company. Our native AI-powered Computer-Aided Drug Discovery (CADD) expertise and this new experimental unit will enable us to lead integrated drug discovery programs, from virtual screening to experimental validation. This unit will be built and managed by just hired in September, Nicolas Babault, former team leader at the Icahn School of Medicine at Mount Sinai – New York City.
Publié il y a 5 ans
November 2018
The Netherlands embassy hosts SYNSIGHT for the Erasme-Descartes conference in collaboration with the French embassy. SYNSIGHT presents how AI is incorporated in its proprietary drug discovery platform.
Recherche de partenaires
Voir les informations détailléesPlateforme intégrée de criblage High-Content et Intelligence artificielle pour la modulation de Portein-Protein Interaction
Type de partenariat
Offre
Objet du partenariat
Technologique
Réseau (0)
Il n'y a pas encore d'organisations dans le réseau.
